Date: Jan 01, 2012 Source:
The company had planned to begin trading this week on the Nasdaq under ticker symbol CGIX, with William Blair & Co. and Baird serving as co-lead underwriters. It reports around a $16 million net loss on over $2 million in revenue for the first nine months of 2011. www.cancergenetics.com
